Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer

X. Cynthia(Washington University in St. Louis), Matthew J. Ellis(Guardant (United States)), Alshad S. Lalani(Puma Biotechnology (United States)), Feng Gao(Washington University in St. Louis), Matthew P. Goetz(Mayo Clinic), Carey K. Anders(Duke University), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), Shana Thomas, Hussam Al‐Kateb(Washington University in St. Louis), Mark D. Pegram(Stanford University), Christy Russell(University of Southern California), Timothy Pluard(Southwestern Medical Center), Philippe L. Bédard(Princess Margaret Cancer Centre), Melody Cobleigh(Rush University Medical Center), Andres Forero(University of Alabama at Birmingham), Polly Niravath(Houston Methodist), Melinda L. Telli(Stanford University), Kimberly C. Banks(Guardant (United States)), Caroline Bumb(Washington University in St. Louis), Gretchen Kimmick(Johns Hopkins University), Daniel F. Hayes(University of Michigan–Ann Arbor), Eric P. Winer(University of Vermont), Rachel A. Freedman(Dana-Farber Cancer Institute), Michael Naughton(Boston College), Richard Bryce(Puma Biotechnology (United States)), J. L. Anderson(Washington University in St. Louis), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Ron Bose(University Hospitals Seidman Cancer Center), Kimberly Blackwell(Duke University), John D. Pfeifer(Washington University in St. Louis)
Clinical Cancer Research
July 5, 2017
Cited by 191


Related Papers